Preparation of blood-brain barrier-permeable paclitaxel-carrier conjugate and its chemotherapeutic activity in the mouse glioblastoma model

MedChemComm

Volumn 2, Issue 4, 2011, Pages 270-273

  Jin, Juyoun ^b   Lee, Woo Sirl ^a   Joo, Kyeung Min ^c   Maiti, Kaustabh K ^a   Biswas, Goutam ^a   Kim, Wanil ^a   Kim, Kyong Tai ^a   Lee, Se Jeong ^b   Kim, Kang Ho ^b   Nam, Do Hyun ^b   Chung, Sung Kee ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; PACLITAXEL; SORBITOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; COVALENT BOND; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG PENETRATION; DRUG SYNTHESIS; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 79953873279     PISSN: 20402503     EISSN: 20402511     Source Type: Journal    
DOI: 10.1039/c0md00235f     Document Type: Article

References (40)

1. (a) M. C. Wani, H. L. Taylor, M. E. Wall, P. Coggon and A. T. McPhail, J. Am. Chem. Soc., 1971, 93, 2325;
2. (b) P. B. Schiff, J. Fant and S. B. Horowitz, Nature, 1979, 277, 665.
3. (a)K. C. Nicolaou, W.-M. Dai and R. K. Guy, Angew. Chem., Int. Ed. Engl., 1994, 33, 15;
4. (b) M. Skwarczynski, Y. Hayashi and Y. Kiso, J. Med. Chem., 2006, 49, 1;
5. (c) D. G. I. Kingston, J. Org. Chem., 2008, 73, 3975;
6. (d) I. Ojima, Acc. Chem. Res., 2008, 41, 108.
7. (a) A. K. Singla, A. Garg and D. Aggarwal, Int. J. Pharm., 2002, 235, 179;
8. (b) M. S. Lesniak and H. Brem, Nat. Rev. Drug Discovery, 2004, 3, 499.
9. (a) S. Tsukita, M. Furuse and M. Itoh, Nat. Rev. Mol. Cell Biol., 2001, 2, 285;
10. (b) W. M. Pardridge, Drug Discovery Today, 2007, 12, 54.
11. (a) R. Z. Yusuf, Z. Duan, D. E. Lamendola, R. T. Penson and M. V. Seiden, Curr. Cancer Drug Targets, 2003, 3, 1;
12. (b) G. Szakacs, J. K. Paterson, J. A. Ludwig, C. Booth-Genthe and M. M. Gottesman, Nat. Rev. Drug Discovery, 2006, 5, 219.
13. R. Cecchelli, V. Berezowski, S. Lundquist, M. Culot, M. Renftel, M.- P. Dehouck and L. Fenart, Nat. Rev. Drug Discovery, 2007, 6, 650.
14. K. M. Joo, S. Y. Song, K. Park, M. H. Kim, J. Jin, B. G. Kang, M. J. Jang, G. S. Lee, M. S. Kim and D. H. Nam, Int. J. Oncol., 2008, 33, 705.
15. (a) Ü. Langel, Ed. Handbook of Cell-Penetrating Peptides, 2nd Edition, CRC Press, Boca Raton, 2007;
16. (b) P. A. Wender, W. C. Galliher, E. A. Goun, L. R. Jones and T. H. Pillow, Adv. Drug Delivery Rev., 2008, 60, 452;
17. (c) I. Nakase, T. Takeuchi, G. Tanaka and S. Futaki, Adv. Drug Delivery Rev., 2008, 60, 598.
18. (a) W. Pan, A. J. Kastin, T. C. Zankel, P. Van Kerkhof, T. Terasaki and G. Bu, J. Cell Sci., 2004, 117, 5071;
19. (b) S. Ito, S. Ohtsuki and T. Terasaki, Neurosci. Res., 2006, 56, 246.
20. (a) K. K. Maiti, O. Y. Jeon, W. S. Lee, D. C. Kim, K. T. Kim, T. Takeuchi, S. Futaki and S. K. Chung, Angew. Chem., Int. Ed., 2006, 45, 2907;
21. (b) K. K. Maiti, W. S. Lee, T. Takeuchi, C. Watkins, M. Fretz, D. C. Kim, S. Futaki, A. Jones, K. T. Kim and S. K. Chung, Angew. Chem., Int. Ed., 2007, 46, 5880;
22. (c) G. Biswas, O. Y. Jeon, W. S. Lee, D. C. Kim, K. T. Kim, S. Lee, S. Chang and S. K. Chung, Chem.-Eur. J., 2008, 14, 9161;
23. (d) W. S. Lee, C. N. Im, Q. Y. Teng, Y. T. Chang, D. C. Kim, K. T. Kim and S. K. Chung, Mol. BioSyst., 2009, 5, 822.
24. J. K. Im, W. Kim, K. T. Kim and S. K. Chung, Chem. Commun., 2009, 4669.
25. (a) N. F.Margi and D. G. I. Kingston, J. Nat. Prod., 1988, 51, 298;
26. (b) H. M. Deutsch, J. A. Glinski, M. Hernandez, R. D. Hauwitz, V. L. Narayanan, M. Suffness and L. H. Zalkow, J. Med. Chem., 1989, 32, 788;
27. (c) T. A. Kirschberg, C. L. VanDeusen, J. B. Rothbard, M. Yang and P. A. Wender, Org. Lett., 2003, 5, 3459;
28. (d) S. Wang, N. Z. Zhelev, S. Duff and P. M. Fischer, Bioorg. Med. Chem. Lett., 2006, 16, 2628.
29. A. K. Pathak, V. Pathak, L. E. Seitz, K. N. Tiwari, M. S. Akhtar and R. C. Reynolds, Tetrahedron Lett., 2001, 42, 7755.
30. I. B. Paek, H. Y. Ji, M. S. Kim, G. S. Lee and H. S. Lee, J. Sep. Sci., 2006, 29, 628.
31. (a) D. S. Grant, T. L. Williams, M. Zahaczewsky and A. P. Dicker, Int. J. Cancer, 2003, 104, 121;
32. (b) D. Belotti, V. Vergani, T. Drudis, P. Borsotti, M. R. Pitelli, G. Viale, R. Giavazzi and G. Taraboletti, Clin. Cancer Res., 1996, 2, 1843;
33. (c) M. J. Son, H. S. Song, M. H. Kim, J. T. Kim, C. M. Kang, J. W. Jeon, S. Y. Park, Y. J. Kim, M. D. Groves, K. Park, J. H. Kim and D. H. Nam, Int. J. Oncol., 2006, 28, 1385.
34. E. M. Kemper, A. E. van Zandbergen, C. Cleypool, H. A. Mos, W. Boogerd, J. H. Beijnen and O. van Tellingen, Clin. Cancer. Res., 2003, 9, 2849.
35. (a) R. L. Juliano and V. Ling, Biochim. Biophys. Acta, Biomembr., 1976, 455, 152;
36. (b) C. Cordon-Cardo, J. P. O'Brien, J. Boccia, D. Casals, J. R. Bertino and M. R. Melamed, J. Histochem. Cytochem., 1990, 38, 1277;
37. (c) N. Kartner, J. R. Riordan and V. Ling, Science, 1983, 221, 1285.
38. (a) H. Jiang, W. Tao, M. Zhang, S. Pan, J. R. Kanwar and X. Sun, Cancer Invest., 2010, 28, 74;
39. (b) T. Browder, C. E. Butterfield, B. M. Kraling, B. Shi, B. Marshall, M. S. O'Reilly and J. Folkman, Cancer Res., 2000, 60, 1878.
40. D. P. Samuel, P. Y. Wen and M. W. Kieran, Expert Opin. Invest. Drugs, 2009, 18, 973.